FluidForm Bio
About this raise
FluidForm Bio, with a valuation of $25 million, is raising funds on StartEngine. The company is pioneering 3D bioprinting technology to cure type 1 diabetes. FluidForm Bio’s FRESH technology enables the creation of insulin-producing tissue that is implanted under the skin to address type 1 diabetes. The technology is minimally invasive and retrievable and has been tested on small animals successfully. Michael Graffeo and Adam Feinberg founded FluidForm Bio in June 2018. The current crowdfunding campaign has a minimum target of $124,000 and a maximum target of $1.24 million. The campaign proceeds will be used for research and development, company employment, and working capital.
Investment Overview
Committed : $15,008
Deal Terms
Total Commitments
- Platform
- StartEngine
- Start Date
- 04/02/2025
- Close Date
- 07/01/2025
$124,000
$1,235,000
$500
Convertible Note
Growth Stage
RegCF
$25,000,000
20%
Company & Team
Company
- Year Founded
- 2018
- Industry
- Healthcare & Pharmaceuticals
- Tech Sector
- Distribution Model
- B2B2C
- Margin
- High
- Capital Intensity
- High
Financials
- Revenue -91.3% YoY
-
$168,783
as of FY2024
- Monthly Burn
-
$70,000
as of Mar '25
-
Runway
-
6.6 months
as of Mar '25
- Gross Margin
-
86%
as of FY2024
Upgrade to gain access
-
$12.50 /month
billed annually - Free portfolio tracking, data-driven ratings, AI analysis and reports
- Plan Includes:
- Everything in Free, plus
- Company specific
Kingscrowd ratings and analyst reports
- Deal explorer and side-by-side comparison
- Startup exit and failure tracking
- Startup market filters and historical industry data
- Advanced company search ( with ratings)
- Get Edge Annual
Edge
Ratings 
Company Funding & Growth
Funding history
- Total Prior Capital Raised
- $13,600,419
- VC Backed?
- No
| Close Date | Platform | Valuation | Total Raised | Security Type | Status | Reg Type |
|---|---|---|---|---|---|---|
| 07/01/2025 | StartEngine | $25,000,000 | $15,008 | Convertible Note | Active | RegCF |